2020
DOI: 10.1016/j.biopha.2020.110797
|View full text |Cite
|
Sign up to set email alerts
|

The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
31
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 39 publications
(31 citation statements)
references
References 72 publications
0
31
0
Order By: Relevance
“…Several clinical trials demonstrated that lenvatinib could significantly prolong the median OS of patients with HCC, and it even showed better clinical efficacy than sorafenib 8,25,26 . Moreover, as reported, when combined with immune checkpoint therapy, the prognosis of patients with HCC had been greatly improved 11,12,27 . In addition, pervious research demonstrated that lenvatinib monotherapy could increase tumor‐infiltrating macrophages and CD8 + T cells through mice model in anaplastic thyroid cancer 28 .…”
Section: Discussionmentioning
confidence: 92%
See 1 more Smart Citation
“…Several clinical trials demonstrated that lenvatinib could significantly prolong the median OS of patients with HCC, and it even showed better clinical efficacy than sorafenib 8,25,26 . Moreover, as reported, when combined with immune checkpoint therapy, the prognosis of patients with HCC had been greatly improved 11,12,27 . In addition, pervious research demonstrated that lenvatinib monotherapy could increase tumor‐infiltrating macrophages and CD8 + T cells through mice model in anaplastic thyroid cancer 28 .…”
Section: Discussionmentioning
confidence: 92%
“… 10 On the other hand, immune modulatory effects also played a vital role in tumor development. Several research had already showed that when combined with immune‐checkpoint inhibitors, lenvatinib could greatly enhance its antitumor effect 11 , 12 ; other reports indicated lenvatinib itself has ability to alleviate the immune suppression 13 and further affects the immune cells 14 so as to improve the prognosis of patients with tumor burden. However, there is no relevant research explains how lenvatinib regulates the immune status of HCC patients.…”
Section: Introductionmentioning
confidence: 99%
“…Several tyrosine kinase inhibitors, such as sorafenib, regorafenib, and lenvatinib, have been approved for the treatment of advanced HCC [ 25 , 26 ]. Therefore, the development of the abovementioned tyrosine kinase inhibitors may offer therapeutic benefits for patients with HCC.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, the benefits remain limited and novel treatment strategies for patients with advanced HCC are urgently required. Numerous studies are examining treatment concepts using combinations of LEN with immune checkpoint inhibitors (ICIs), with preliminary results showing that the combinations were well-tolerated and encouraging (13)(14)(15). In 104 patients enrolled in the phase Ib trial of LEN plus pembrolizumab, the confirmed objective response rate (ORR) was 46% and median OS was 22 months (13).…”
Section: Introductionmentioning
confidence: 99%